Tirbanibulin (Klisyri, Almirall) has been approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of actinic keratosis on the face or scalp.
Jennifer Barrett
Advertisement
Jennifer Barrett is senior editor for Drug Topics.
Articles by Jennifer Barrett
Advertisement
Latest Updated Articles
FDA approves topical for actinic keratosisDecember 16th 2020
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
3
Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study
4
Sun, Science, and Skin: Dermatology's Biggest Spotlights This June
5